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Introduction
The incidence of all invasive cervical cancers and squa-
mous cell cancers has decreased over the last few
decades. In this context, cervical adenocarcinoma stands
out, because its incidence has been increasing in recent
years, particularly in younger women, despite widespread
screening programs and histology-specific cancer regis-
tration [1–4]. The epidemiologic factors underlying this
differential trend are yet to be investigated. According
the data of the Taiwan Cancer Registry, the proportion
of adenocarcinomas relative to squamous cell carcino-
mas and to all cervical cancers was 1.6 between 1996
and 2005; the incidence of squamous cell carcinoma has
declined but that of adenocarcinoma in the population
at risk has steadily increased over this period.
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SUMMARY
Objective: To examine the relationship between human papillomavirus (HPV) and Epstein-Barr virus (EBV)
infections in relation to age of patients with cervical adenocarcinoma.
Materials and Methods: Thirty samples of human cervical adenocarcinoma tissue were collected from the 
surgical pathology archive at Taipei Veterans General Hospital from 1996 to 2008. All samples were examined
for EBV, HPV-16 and HPV-18 E6 DNA by conventional and real-time quantitative polymerase chain reaction
assays.
Results: HPV-16 DNA was detected in 10 cases (33.3%), HPV-18 DNA in 12 cases (40%), and EBV DNA in
three cases (10%); there were negative findings in seven cases (23.3%). EBV combined with HPV-16 or HPV-18
was also detected in one case each. No link could be demonstrated between HPV and EBV in endocervical
lesions. When 20 patients £ 45 years old were compared with 10 patients > 45 years old, HPV-18 E6 DNA was
detected in 45% vs. 30% (9/20 vs. 3/10), HPV-16 E6 DNA in 40% vs. 20% (8/20 vs. 2/10), EBV DNA in 10% vs. 10%
(2/20 vs. 1/10), and no virus DNA was detected in 10% vs. 50% (2/20 vs. 5/10). HPV and EBV were significantly
more common in younger women (p < 0.001).
Conclusion: HPV-18 plays a major role in adenocarcinomas at any age. A high prevalence of HPV DNA is signif-
icantly associated with cervical adenocarcinoma, especially in younger women. The results do not support a role
for EBV in cervical adenocarcinogenesis or any relationship between EBV and HPV infection in adenocarcinoma.
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HPV and EBV Infections and Age
Human papillomaviruses (HPVs) are considered to
be necessary and central etiologic agents for cervical
carcinogenesis according to results of epidemiologic
and molecular biologic studies [5–7]. To date, more
than 100 HPV genotypes have been characterized and
more than 20 different types have been isolated from
patients with cervical carcinoma [8,9]. HPV-16, HPV-18,
HPV-58, HPV-45, HPV-52 and HPV-31 have been fre-
quently associated with cervical carcinoma in Taiwan.
Squamous cell carcinoma of the cervix is linked to
infection with oncogenic types of HPV, but the patho-
genesis of adenocarcinoma is less well understood.
The reported prevalence of HPV DNA in adenocarci-
noma varies significantly from 32% to 100%, depending
on the detection method used. A strong association
between a sexually transmitted agent (HPV) and the
risk of developing cervical squamous cell carcinoma
has been clearly established; however, the relationship
between HPV and cervical adenocarcinoma remains un-
certain [4]. Some reports have shown that the epidemi-
ologic cofactors for cervical adenocarcinoma include
HPV positivity, no history of schooling, poor hygiene,
sexual behavior-related variables, long-term use of hor-
monal contraception, high parity, and herpes simplex
virus-2 seropositivity [4,10]. However, little information
is available concerning the cofactors and geographic
variation of HPV types in adenocarcinoma.
Epstein-Barr virus (EBV) receptors have been found
in the cervical epithelium. It is a ubiquitous herpes virus
associated with a number of human malignancies, and
its DNA has been detected in other tumors, such as car-
cinomas from the tonsils, salivary glands and thymus,
and in malignancies of the female genital tract [11].
van den Brule et al [12] suggested the existence of a
previously undescribed association between EBV and
squamous cell carcinoma of the cervix, but Payne et al
[13] and other researchers [14,15] have failed to con-
firm this finding.
In this study, we used highly sensitive polymerase
chain reaction (PCR)-based methods, including E6
type-specific primers and probes, to detect HPV and
EBV DNA in cervical adenocarcinoma. The prevalence
and possible etiologic link between HPV, EBV and age
were examined in Taiwanese women.
Materials and Methods
Tissue samples
Thirty samples of human cervical adenocarcinoma tis-
sue were collected from the surgical pathology archive
at Taipei Veterans General Hospital from January 1996
to January 2008. The specimens were obtained through
radical surgery, tumor removal, and debulking. Small
biopsies unsuitable for further evaluation were excluded.
The sampled cases had undergone complete clinico-
pathologic evaluations, including immunophenotypic
and some molecular studies, to ascertain the diag-
nosis and rule out double tumors. Hematoxylin and
eosin-stained slides of each primary case were reviewed
and classified according to the 2003 World Health
Organization classification of tumors. All studies were
approved by the institutional review board of Taipei
Veterans General Hospital.
DNA extraction
One adenocarcinoma tissue section (6 mm thick) was
cut from each paraffin block using a disposable micro-
tome blade and placed on a glass slide. The slides were
then baked in an oven at 65°C for 30 minutes, and
then deparaffinized by serial xylene and ethanol washes,
according standard pathologic procedures. After re-
hydration, the slides were left to air dry at room tem-
perature. Cellular proteins were digested in 10 mL of
proteinase K (1 mg/mL) applied to the slide at room
temperature. The cellular debris, including DNA, was
aspirated by pipette and placed in a 100-mL microtube
containing 15 mL of GeneReleaser (BioVentures Inc.,
Murfreesboro, TN, USA). DNA extraction was performed
in a traditional 96-well PCR machine (Palm-Cycler;
Corbett Research, Sydney, NSW, Australia) under the
following conditions: 50°C for 180 minutes, 65°C for
30 seconds, 8°C for 30 seconds, 65°C for 90 seconds,
97°C for 180 seconds, 80°C for 60 seconds, 65°C for
180 seconds, 97°C for 60 seconds, 65°C for 60 seconds,
and 80°C for 60 minutes, in accordance with the manu-
facturer’s protocol. The suitability of samples for PCR
amplification was ascertained by testing for the β-globin
gene. Successful amplification of the β-globin gene frag-
ments indicated that the DNA sample was adequate for
PCR analysis and that no PCR inhibitors were present.
PCR amplification
Purified genomic DNA was amplified by PCR for the
EBV, HPV-16 and HPV-18 E6 genes, as well as for the
internal reference gene, β-globin. EBV nuclear antigen
primers were used for EBV amplification: primer, 5-
AGTCATCATCATCCGGGTCTCC-3; and probe, 5-
(FAM)-CGCAGGCCCCCTCCAGGTAGAA-(Black Hole
Quencher)-3. HPV primers were as follows: HPV-16
E6 primer, 5-GAACCGGACAGAGCCCATTAC-3, and
probe, 5-(CY5)-ACAACCGAAGCGTAGAGTCACACT-
TGC-(Black Hole Quencher)-3; HPV-18 E6 primer,
5-GAGGCCAGTGCCATTCGTG-3, and probe, 5-
(ROX)-CAACCGAGCACGACAGGAACGACT-(Black
Hole Quencher)-3.
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Multiplex real-time PCR
Each PCR reaction mixture contained 10 mL of 2X
Qiagen Multiplex PCR Master mix (Qiagen Inc.,
Valencia, CA, USA), 1 mL of template DNA, and 0.5M
(final concentration) of each primer pair and their cor-
responding probes. The final PCR mixture volume was
made up to 20 mL with deionized water. The PCR reac-
tion was programmed as: (1) Taq activation, 95°C 
for 14 minutes; and (2) amplification cycles, 94°C for 
15 seconds, 58°C for 50 seconds, repeat for 60 cycles.
The PCR reaction was run in duplicate in a Bio-Rad
DNA Engine thermocycler coupled with a Chromo4
detector (Bio-Rad Gradient Real-Time PCR; MJ Research,
Waltham, MA, USA). The PCR machine was controlled
by a Windows-based laptop running Opticon Monitor
3.1 software (MJ Research).
Statistical analysis
The patients were divided into two groups: those ≤ 45
years old and those >45 years old. Differences between
the two groups were tested by univariate analysis using
χ2 tests and Fisher’s exact tests, as appropriate. Overall
survival was analyzed by log-rank tests. A p value of
< 0.05 was considered statistically significant.
Results
Coexistence of cervical intraepithelial neoplasia (CIN)
with HPV-16 DNA was detected in three of 30 cases 
of adenocarcinoma. The results of quantitative PCR
analysis for HPV-18, HPV-16 and EBV DNA are shown
in Figures 1, 2 and 3, respectively. HPV-16 DNA was
detected in 10 cases (33.3%), HPV-18 DNA in 12 cases
(40%), and EBV in three cases (10%); there were negative
findings in seven cases (23.3%). EBV combined with
HPV-16 or HPV-18 was also detected in one case each.
Detection of virus DNA was significantly associated
with younger age (p < 0.001).
When comparing the 20 patients aged ≤ 45 years
with the 10 patients aged > 45 years, we found HPV-18
E6 DNA in 45% vs. 30% (9/20 vs. 3/10), HPV-16 E6
DNA in 40% vs. 20% (8/20 vs. 2/10), EBV in 10% vs.
10% (2/20 vs. 1/10), and negative findings of virus
DNA in 10% vs. 50% (2/20 vs. 5/10) (Table). Overall sur-
vival of the two groups is shown in Figure 4. Patients
aged ≤ 45 years had significantly shorter overall sur-
vival than those aged > 45 years (p = 0.013). No sig-
nificant differences between the incidences of HPV-16
and HPV-18 DNA were noted in adenocarcinoma, but
only HPV-16 was detected in cases with coexisting CIN.
These results suggest that HPV-16 can occur in both
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Figure 1. Quantitative polymerase chain reaction for human
papillomavirus-18.
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Figure 3. Quantitative polymerase chain reaction for Epstein-
Barr virus.
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Figure 2. Quantitative polymerase chain reaction for human
papillomavirus-16.
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CIN and adenocarcinoma, while HPV-18 occurs pre-
dominantly in adenocarcinoma and mainly in younger
women. There was no significant link between the
presence of EBV DNA and adenocarcinoma or HPV
infection.
Discussion
The incidence of squamous cell carcinoma has decreased
over the last few decades, while the incidence of cervical
adenocarcinoma has increased in the United States since
the early 1970s, especially in younger women [16,17].
This observation may be explained by changes in sex-
ual behavior, HPV infection or an insufficient ability 
to detect a substantial proportion of adenocarcinoma
precursor lesions in current screening practices [10].
HPV DNA, mainly HPV-16, has been detected in
squamous cell carcinoma of the uterine cervix and its
precursor lesion, CIN [16]. Coexistence of CIN with
adenocarcinoma or the presence of HPV in established
human cell lines derived from adenocarcinoma sug-
gests that HPV could play the same etiologic role in
adenocarcinoma as in squamous cell carcinoma.
HPV types 16 and 18 are those most often related
to the development of squamous, adeno- and small
cell carcinoma of the cervix and to advanced metasta-
sis of cervical cancer [18]. Schiffman et al [5] reported
that adenocarcinoma was more often associated with
HPV type 18 than with squamous cell carcinoma. HPV-
18 has also been shown to be associated with a poorer
prognosis than other HPV types [6,7]. In this study,
three of 10 cases with HPV-16 DNA had associated
CIN, compared with none of the cases with HPV-18
DNA. These results suggest that HPV-18 is a depen-
dent risk factor for the development of adenocarcinoma,
whereas HPV is central to the carcinogenesis of both
histologic types of cervical cancer. These distribution
results suggest that HPV is central to the carcinogenesis
Figure 4. Overall survival.
Table. Detection of human papillomavirus (HPV)-16, HPV-18 and Epstein-Barr virus (EBV) in cervical adenocarcinoma 
in relation to age*
Patients ≤ 45 yr (n = 20) Patients > 45 yr (n = 10) p
Age, median (range) (yr) 40.6 (32–44) 47 (47–69)
BMI 0.89
< 18.5 2 (10) 1 (10)
18.5–24.9 16 (80) 7 (70)
≥ 25 2 (10) 2 (20)
Smoking habit 0.66
Non-smoker 14 (70) 6 (60)
Ex-smoker 4 (20) 2 (20)
Smoker 2 (10) 2 (20)
Virus DNA < 0.001
Positive
HPV-16 8 (40) 1 (10)
HPV-18 8 (40) 3 (30)
EBV 1 (5) 0
HPV-16 + EBV 0 1 (10)
HPV-18 + EBV 1 (5) 0
Negative 2 (10) 5 (50)
*Data are presented as n (%). BMI = body mass index.
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of adenocarcinoma and is associated with a poorer prog-
nosis (p = 0.013) in younger women, compared with
older women. Moreover, no viral DNA was detected in
five of 10 patients (50%) > 45 years old. This may indi-
cate that other epidemiologic cofactors are related to
adenocarcinoma development in older women. However,
further studies are needed to confirm the results of this
small series.
Although little is known about the molecular genetic
events involved in the pathogenesis of cervical adeno-
carcinoma after HPV infection, it is well established that
expression of the high-risk HPV E6 and E7 oncoproteins
in keratinocytes (squamous cells) disrupts the function
of the cell cycle-regulating proteins p53 and pRB,
respectively [19]. It is assumed that the same mecha-
nism of HPV-related carcinogenesis occurs in cervical
glandular epithelium.
Furthermore, the presence of EBV in tumor epithe-
lium was detected in only three cases, and was combined
with HPV-16 or HPV-18 in two cases. This finding sug-
gests that this agent does not play a role in the patho-
genesis of neoplasms of the cervix and that it has no
significant relationship with HPV type. Although this
study indicates that EBV is unlikely to be a major etiologic
factor in the development of cervical adenocarcinoma
in this population, it does not necessarily exclude its
role elsewhere [20].
In conclusion, our findings confirm that HPV is a
central cause of cervical adenocarcinoma and that the
same HPV types known to be involved in squamous cell
carcinoma are also involved in cervical adenocarcinogen-
esis. The introduction of HPV testing and Papanicolaou
tests to primary screening programs for cervical cancer
should improve their efficiency for detecting precancer-
ous glandular lesions, especially in younger women.
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